JAKARTA - PT Diagnos Laboratorium Utama Tbk (DGNS) will conduct rights issue of a maximum of 921 billion new shares worth IDR 25 per share. With an offering price set to IDR 505, the transaction value hit IDR 465.10 billion.

In the prospectus quoted today (18/4), this corporate action plan still awaits approval from shareholders, which will be obtained in the Extraordinary General Meeting of Shareholders on Friday (19/4). The proceeds of this rights issue will be utilised to take over 97.97% of Asa Ren Pte Ltd through non-cash capital investment (inbreng), shares purchase of Aa Ren from Asa Ren’s shareholders, and extra working capital for the company.

The plan of acquisition of Asa Ren costs USD 24.10 million, or equal to IDR 357.89 billion, with exchange rate of IDR 14,850 per USD. They consist of inbreng transaction worth IDR 322.10 billion (USD 21.69 million) and shares acquision worth IDR 35.78 billion (USD 2.41 million).

Asa Ren is known as an experimental research and development company engaged in the medical industry. This company is under Singaporean law, established on March 1, 2021, with a subsidiary named PT Asa Ren Global Nusantara (ARGN). After this acquisition, the subsidiary of Asa Ren will then be listed as DGNS’s subsidiary, as well.

As of now, shareholders of DGNS include PT Bunda Investama Indonesia of 38.80%, PT Bundamedik Tbk (BMHS) of 41.20%, and the public of 20%. After this rights issue, DGNS will claim 99.43% of Asa Ren.

This transaction value is equal to 182.98% of total equity of DGNS as of December 2023, worth IDR 195.59 billion. (LK/ZH)